ACS Nano,
Journal Year:
2023,
Volume and Issue:
17(2), P. 843 - 884
Published: Jan. 4, 2023
Immunotherapy
continues
to
be
in
the
spotlight
of
oncology
therapy
research
past
few
years
and
has
been
proven
a
promising
option
modulate
one's
innate
adaptive
immune
systems
for
cancer
treatment.
However,
poor
delivery
efficiency
agents,
potential
off-target
toxicity,
nonimmunogenic
tumors
significantly
limit
its
effectiveness
extensive
application.
Recently,
emerging
biomaterial-based
drug
carriers,
including
but
not
limited
cells
bacteria,
are
expected
candidates
break
dilemma
immunotherapy,
with
their
excellent
natures
intrinsic
tumor
tropism
immunomodulatory
activity.
More
than
that,
tiny
vesicles
physiological
components
derived
from
them
have
similar
functions
source
due
inheritance
various
surface
signal
molecules
proteins.
Herein,
we
presented
representative
examples
about
latest
advances
employed
cells,
derivatives.
Simultaneously,
opportunities
challenges
bacteria-based
carriers
discussed
provide
reference
future
application
immunotherapy.
Chemical Society Reviews,
Journal Year:
2023,
Volume and Issue:
52(19), P. 6617 - 6643
Published: Jan. 1, 2023
This
review
summarizes
the
strategies
for
surface
chemical
modification
of
bacteria
and
advanced
functions
achieved
by
modifying
specific
components
highlights
applications
modified
bioimaging,
diagnosis,
therapy.
Nature Communications,
Journal Year:
2022,
Volume and Issue:
13(1)
Published: Dec. 17, 2022
Abstract
Methods
capable
of
manipulating
bacterial
colonization
are
great
significance
for
modulating
host-microbiota
relationships.
Here,
we
describe
a
strategy
in-situ
chemical
reaction-mediated
covalent
localization
bacteria.
Through
simple
one-step
imidoester
reaction,
primary
amino
groups
on
surface
can
be
converted
to
free
thiols
under
cytocompatible
conditions.
Surface
thiolation
is
applicable
modify
diverse
strains
and
the
number
introduced
per
bacterium
easily
tuned
by
varying
feed
ratios.
These
chemically
reactive
bacteria
able
spontaneously
bond
with
mucous
layer
catalyst-free
thiol-disulfide
exchange
between
mucin-associated
disulfides
newly
show
level-dependent
attachment.
Bacteria
optimized
9.3
×
10
7
cell
achieve
170-fold
higher
attachment
in
mucin-enriched
jejunum,
challenging
location
gut
microbiota
colonize.
As
proof-of-concept
application
transplantation,
bonding-assisted
an
oral
probiotic
jejunum
generates
improved
remission
jejunal
mucositis.
Our
findings
demonstrate
that
transforming
provides
approach
control
localization,
which
highly
desirable
developing
next-generation
living
bioagents.
Nano Letters,
Journal Year:
2022,
Volume and Issue:
22(12), P. 5055 - 5064
Published: May 18, 2022
Oncolytic
viruses
(OVs)
have
been
widely
used
as
anticancer
therapeutics
because
of
their
systemic
immune
responses
during
viral
replication.
However,
the
low
enrichment
OVs
within
tumors
and
limited
activation
hindered
clinical
application.
Herein,
we
proposed
concept
bacteria-assisted
targeting
to
tumors,
with
liposome-cloaked
oncolytic
adenoviruses
(OAs)
conjugated
onto
tumor-homing
Escherichia
coli
BL21
(designated
E.
coli-lipo-OAs)
for
enhanced
cancer
immunotherapy.
Notably,
OAs
transported
by
self-propelled
bacterial
microbe
vehicles
in
coli-lipo-OAs
a
nonsmall
cell
lung
tumor
can
be
potentiated
more
than
170-fold
compared
that
intravenously
injected
bare
OAs.
In
vivo
studies
further
revealed
administered
significantly
antitumor
immunity
through
bacterial–viral-augmented
responses.
Our
findings
suggest
self-driving
vehicle
delivery
system
potent
platform
developing
future
biotherapeutics
at
level.
